NEW YORK (GenomeWeb News) – NextGen Sciences and Expression Pathology will team up to offer protein biomarker services for scientists working with formalin-fixed paraffin-embedded tissue samples, Expression Pathology said today.
The collaborative agreement will allow customers to send their FFPE samples to either company.
Expression Pathology will process samples using its Liquid Tissue MS protein Prep and Director laser micro-dissection technologies. These proteins then will be analyzed for healthy versus diseased or treated versus untreated samples using NextGen’s LC-MS/MS technology.
Immunohistochemistry can take several months to produce antibodies against the proteins, the company said, but the coupled service offering can save time because it does not require antibodies.
“Our combined services will aid in the most challenging task of selecting the appropriate biomarkers for specific drug development programs,” NextGen CEO Mike Pisano said in a statement.